Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (68)

2024

  1. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

    Molecular Cancer, Vol. 23, Núm. 1

  2. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  3. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  4. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

  5. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  6. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  7. Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic

    Archives of Gynecology and Obstetrics, Vol. 310, Núm. 1, pp. 577-586

  8. Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2945-2953

  9. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2023

  1. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 34, Núm. 10, pp. 833-848

  2. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

  3. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  4. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

  5. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4419-4429

  6. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study

    European Journal of Cancer, Vol. 190

2022

  1. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

    Journal for immunotherapy of cancer, Vol. 10, Núm. 5

  2. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258

  3. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials

    European Journal of Cancer, Vol. 163, pp. 98-107

  4. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  5. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 174, pp. 221-231